Status: Recruiting
CD4^LVFOXP3 in Participants With IPEX
This first-in-human, Phase 1 clinical trial will test the feasibility of the manufacturing and the safety of the administration of CD4\^LVFOXP3 in up to 30 evaluable human participants with IPEX and evaluate the impact of the CD4\^LVFOXP3 infusion on the disease.
Participants needed: 30
Trial details
Phase: Phase 1Age: 4-35Biological sex: MaleType: InterventionalSponsor: Bacchetta, Rosa, MDUpdated: May 22, 2025Locations: 1
Eligibility criteria
Body weight greater than 8 kg, unless assessed as able to tolerate leukapheresis [+8]
Medical instability [+7]